Global Injectable Drug Delivery Market By Device Type (Conventional and Self-injection), By Formulation (Novel drugs delivery, Conventional drug delivery, and Other Formulations), By End-User (Home Care, Hospitals, Diagnostic Laboratories, Research Institutes, and Other End-Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032
- Published date: March 2023
- Report ID: 16898
- Number of Pages: 208
Injectable Drug Delivery Market Overview:
In 2021, the global Injectable Drug Delivery (IDD), market was valued at USD 615,954.8 million. This market is expected to grow at a CAGR of 11.8% between 2023-2032.
Injectable drug delivery (IDD) has seen a significant increase in demand due to the rise in chronic diseases like cancer and diabetes.
For a quicker course of action, injectables are used for the treatment of a variety of diseases including Wilson’s disease and autoimmune diseases, as well as cystic Fibrosis, hemophilia, and hepatitis C. These drugs are able to be administered to unconscious or comatose patients and are therefore preferred over other forms of drug delivery.
Global Injectable Drug Delivery Market Analysis
Device Type Analysis
The devices market can further be divided into conventional injection and self-injection devices. self-injection devices held the largest market share in 2021. This market’s fastest growing segment is that which includes self-injection devices. These devices allow for the management and control at the primary level of many disorders. The needle-free injections are a breakthrough technology that allows for painless administration. This makes this segment one of the most profitable.
Conventional drug delivery systems can be described as solutions, reconstituted/lyophilized formulas, suspensions, or emulsions. Colloid dispersions can be used to deliver novel drugs. These include liposomes and noisome. They also contain polymeric or mixed micelles.
The microparticles have been designed to allow for rapid absorption at the intended location. Colloid dispersions are being used in drug delivery systems in a significant way, as most companies have invested heavily in R&D.
According to end-user applications, there is a fragmented market that includes hospitals, home care, Research institutes, and diagnostic laboratories are the other end-user applications. Self-injection devices, such as auto-injectors or pen-injectors, or needle-free injectors, have made it possible for patients to administer IDD at home.
The majority of market leaders in this market have created devices that allow the administration of insulin using self-injection devices due to the rise in diabetes cases worldwide. This market segment, which included home care settings, was the highest-grossing in 2021.
Key Market Segments
By Device Type
- Novel drugs delivery
- Conventional drug delivery
- Other Formulations
- Home Care
- Diagnostic Laboratories
- Research Institutes
- Other End-Users
Technology has allowed us to create better and more efficient devices. We also have the equipment that is tailored to our patient care needs. Dual-injectable and other technological innovations have enhanced drug delivery through injectables. This has resulted in a rise in demand for injectables.
Market restrictions include injuries and infections caused by needles in syringes. Contaminations due to previous injections or needle-stick injury may lead to serious complications. This can often cause additional obstacles in the management of the disease. Some cases may be better served by oral administration of drugs than injections. They are safer and less toxic.
IDD forms are discouraged further by strict regulatory constraints. Injectables are also being questioned due to concerns about their sterility. This has caused a drop in the number of approved manufacturing facilities for these products, and consequently a shortage of these drugs.
Despite all the limitations, IDD’s market potential is huge due to its numerous benefits and wide applicability across a range of illnesses. Major companies are contributing to the growth of the market by offering injectables in place of oral dosages.
North America held the largest market share of 33% in 2021 and is technologically more equipped to manage a large patient population, which makes them more competitive in this market. The need for better drug delivery systems has been highlighted in this region due to the increasing prevalence of chronic conditions. China and India dominate Asia markets with a variety of product options, with specific modifications made to products to meet patients’ needs. This market has a large population, which means that IDD systems are essential.
Key Regions and Countries covered іn thе rероrt:
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- South America
- Rest of South America
- South Africa
- Rest of MEA
Pfizer Inc., Becton, Terumo Corporation, Baxter International, Inc., Dickinson and Company, Schott AG, and other companies are the key players in this market. Some of the largest players in this market have formed partnerships to allow for easy manufacturing and distribution.
Маrkеt Кеу Рlауеrѕ:
- Baxter International Inc.
- Pfizer Inc.
- Terumo Corporation
- Dickinson and Company
- Schott AG
- Teva Pharmaceuticals Industries Ltd.
- Eli Lilly and Company
- Other Key Players
For the Injectable Drug Delivery Market research study, the following years have been considered to estimate the market size:
Attribute Report Details
Short Term Projection Year
Long Term Projection Year
Competitive Landscape, Revenue analysis, Company Share Analysis, Manufacturers Analysis, Volume by Manufacturers, Key Segments, Key company analysis, Market Trends, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis, strategy for existing players to grab maximum market share, and more.
North America, Europe, Asia-Pacific, South America, Middle East & Africa
United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa
Frequently Asked Questions (FAQ)Q: What is the size of the Injectable Drug Delivery market in 2021?
A: The Injectable Drug Delivery market size is US$ 615,954.8 million in 2021.Q: What is the projected CAGR at which the Injectable Drug Delivery market is expected to grow at?
A: The Injectable Drug Delivery market is expected to grow at a CAGR of 11.8% (2023-2032).Q: List the segments encompassed in this report on the Injectable Drug Delivery market?
A: Market.US has segmented the injectable drug delivery market by geographic (North America, Europe, APAC, South America, and Middle East and Africa). By Device Type, the market has been segmented into Self-injection and Conventional. By Formulation, the market has been further divided into Conventional drug delivery, Novel drugs delivery, and Other Formulations. By End-User, the market has been further divided into Hospitals, Research Institutes, Diagnostic Laboratories, Home Care, and Other End-Users.Q: List the key industry players of the Injectable Drug Delivery market?
A: Baxter International Inc., Pfizer Inc., Terumo Corporation, Dickinson and Company, Becton, Schott AG, Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, and Other Key Players are engaged in the Injectable Drug Delivery market.Q: Which region is more appealing for vendors employed in the Injectable Drug Delivery market?
A: North America is expected to account for the highest revenue share of 33%. Therefore, the Injectable Drug Delivery industry in North America is expected to garner significant business opportunities over the forecast period.Q: Name the key areas of business for Injectable Drug Delivery?
A: The US, India, China, Canada, UK, Japan, & Germany are key areas of operation for the Injectable Drug Delivery Market.Q: Which segment accounts for the greatest market share in the Injectable Drug Delivery industry?
A: With respect to the Injectable Drug Delivery industry, vendors can expect to leverage greater prospective business opportunities through the self-injection devices segment, as this area of interest accounts for the largest market share.
| Single User|
USD / per unit
| Multi User|
USD / per unit
| Corporate User|
USD / per unit
|Report Library Access|
|Data Set (Excel)|
|Company Profile Library Access|
|Free Custumization||No||up to 10 hrs work||up to 30 hrs work|
|Accessibility||1 User||2-5 User||Unlimited|
|Analyst Support||up to 20 hrs||up to 40 hrs||up to 50 hrs|
|Benefit||Up to 20% off on next purchase||Up to 25% off on next purchase||Up to 30% off on next purchase|
|Buy Now ($ 3,499)||Buy Now ($ 4,299)||Buy Now ($ 4,999)|